G
Gerald Spotts
Researcher at Baxter International
Publications - 44
Citations - 2598
Gerald Spotts is an academic researcher from Baxter International. The author has contributed to research in topics: Population & Immune system. The author has an hindex of 21, co-authored 44 publications receiving 2408 citations. Previous affiliations of Gerald Spotts include San Francisco General Hospital & Takeda Pharmaceutical Company.
Papers
More filters
Journal ArticleDOI
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
R. Brad Jones,Lishomwa C. Ndhlovu,Jason D. Barbour,Prameet M. Sheth,Aashish R. Jha,Brian Long,Jessica Wong,Malathy Satkunarajah,Marc Schweneker,Joan M. Chapman,Gabor Gyenes,Bahareh Vali,Martin D. Hyrcza,Feng Yun Yue,Colin Kovacs,Aref Sassi,Mona R. Loutfy,Roberta Halpenny,Desmond Persad,Gerald Spotts,Frederick Hecht,Tae-Wook Chun,Joseph M. McCune,Rupert Kaul,James M. Rini,Douglas F. Nixon,Mario A. Ostrowski +26 more
TL;DR: Blocking the Tim-3 signaling pathway restored proliferation and enhanced cytokine production in HIV-1–specific T cells and represents a novel target for the therapeutic reversal of HIV–1–associated T cell dysfunction.
Journal ArticleDOI
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
Peter William Collins,Victor Blanchette,Krista Fischer,Sven Björkman,Myungshin Oh,Sandor Fritsch,Phillip Schroth,Gerald Spotts,Jan Astermark,Bruce M. Ewenstein +9 more
TL;DR: It is demonstrated that increasing time with a FVIII below 1 IU dL−1 is associated with increased total bleeds and hemarthroses, and has important implications for the management of patients with severe hemophilia.
Journal ArticleDOI
Population pharmacokinetics of recombinant factor VIII : the relationships of pharmacokinetics to age and body weight
Sven Björkman,Myungshin Oh,Gerald Spotts,Phillip Schroth,Sandor Fritsch,Bruce M. Ewenstein,Kathleen M. Casey,Krista Fischer,Victor Blanchette,Peter William Collins +9 more
TL;DR: The relationships of the PK of factor VIII (FVIII) with age and body weight by a population PK model can be used as a basis for PK-based dose tailoring of FVIII in clinical practice, in all age groups, with minimal blood sampling.
Journal ArticleDOI
Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens
Peter William Collins,Sven Björkman,Krista Fischer,Victor Blanchette,Myungshin Oh,Phillip Schroth,Sandor Fritsch,Kathleen M. Casey,Gerald Spotts,Bruce M. Ewenstein +9 more
TL;DR: Knowledge of individual patients’ half‐lives and alteration of frequency of infusions may allow the more cost‐effective use of FVIII and potentially expand access to prophylaxis to a greater number of patients, especially in regions where healthcare resources are scarce.
Journal ArticleDOI
Plasma and albumin-free recombinant factor VIII: Pharmacokinetics, efficacy and safety in previously treated pediatric patients
Victor S. Blanchette,Amy D. Shapiro,R. Liesner,F Hernández Navarro,Indira Warrier,Phillip Schroth,Gerald Spotts,Bruce M. Ewenstein +7 more
TL;DR: In this article, the authors evaluated the pharmacokinetics, efficacy and safety of a plasma-free recombinant FVIII concentrate, ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method, rAHF-PFM], in children < 6 years of age with severe hemophilia.